4//SEC Filing
Actinium Pharmaceuticals, Inc. 4
Accession 0001213900-15-004135
$ATNMCIK 0001388320operating
Filed
May 21, 8:00 PM ET
Accepted
May 22, 5:08 PM ET
Size
18.7 KB
Accession
0001213900-15-004135
Insider Transaction Report
Form 4
DAVE KAUSHIK J
DirectorPresident and CEO
Transactions
- Award
Options to purchase common stock
2015-05-07$2.52/sh+63,063$158,919→ 63,063 totalExercise: $2.52From: 2015-05-07Exp: 2025-05-07→ Common stock (63,063 underlying) - Tax Payment
Common stock
2015-05-07$2.45/sh−7,083$17,353→ 57,083 total - Disposition to Issuer
Common stock
2015-05-07$2.45/sh−27,501$67,377→ 57,083 total - Tax Payment
Common stock
2015-05-07$2.45/sh−16,000$39,200→ 73,083 total - Disposition to Issuer
Common Stock
2015-05-07$2.45/sh−68,000$166,600→ 73,083 total - Disposition to Issuer
Common stock
2015-05-07$2.45/sh−25,000$61,250→ 85,583 total - Award
Options to purchase common stock
2015-05-07$2.52/sh+82,128$206,963→ 82,128 totalExercise: $2.52Exp: 2025-05-07→ Common stock (82,128 underlying) - Tax Payment
Common stock
2015-05-07$2.45/sh−12,500$30,625→ 85,583 total
Footnotes (6)
- [F1]Recipient was granted 41,667 shares of restricted common stock on 1/10/14. As of May 7, 2015, 14,166 shares were vested. Company withheld 7,083 shares to pay tax obligations of award recipient on vested shares. The remaining 27,501 unvested shares of restricted stock were cancelled and a new award of 32,869 options exercisable for shares of common stock were granted to the recipient.
- [F2]11,667 shares vested on 1/10/15 and the share price was $5.17; 833 shares vested on 2/10/15 and the share price was $3.52; 833 shares vested on 3/10/15 and the share price was $2.95; and 833 shares vested on 4/10/15 and the share price was $2.96.
- [F3]Recipient was granted 100,000 shares of restricted common stock on 2/21/14. As of May 7, 2015, 32,000 shares were vested. Company withheld 16,000 shares to pay tax obligations of award recipient on vested shares. The remaining 68,000 unvested shares of restricted stock were cancelled and a new award of 82,128 options exercisable for shares of common stock were granted to the recipient.
- [F4]28,000 shares vested on 2/21/15 and the share price was 3.51; 2,000 shares vested on 3/21/15 and the share price was $2.87; and 2,000 shares vested on 4/21/15 and the share price was $3.08.
- [F5]Recipient was granted 100,000 shares of restricted common stock on 9/16/13, of which 50,000 shares vested on 9/16/14. As of May 7, 2015, an additional 25,000 shares were vested in 2015. Company withheld 12,500 shares to pay tax obligations of award recipient on 2015 vested shares. The remaining 25,000 unvested shares of restricted stock were cancelled and a new award of 30,194 options exercisable for shares of common stock were granted to the recipient.
- [F6]Options vest based on certain miles stones: Filing IND (50%); First Patient in (10%); Hiring of VP-Mfg or other competent person and training so that person is capable of producing Iomab-B (25%); Completion of Actimab-A 1 step labeling (10%); and VP Manufacturing or other competent person to handle manufacturing and logistics of Actimab-A (5%).
Documents
Issuer
Actinium Pharmaceuticals, Inc.
CIK 0001388320
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001388320
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 5:08 PM ET
- Size
- 18.7 KB